FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Clinical Trial Begins to Test Semaglutide for Opioid Use Disorder [NCT06548490]
Voltar à Biblioteca de Pesquisa

Clinical Trial Begins to Test Semaglutide for Opioid Use Disorder [NCT06548490]

November 20, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

Clinical Trial Begins to Test Semaglutide for Opioid Use Disorder [NCT06548490]

A new clinical trial launched by Milton S. Hershey Medical Center is exploring whether semaglutide, a GLP-1 receptor agonist commonly used to treat type 2 diabetes and obesity, can help reduce illicit opioid use among individuals undergoing outpatient treatment for opioid use disorder (OUD). The study aims to provide valuable insights into the potential of peptide therapy as an adjunctive treatment for OUD.

Background

According to the World Health Organization, opioid addiction is a global health crisis affecting millions of people worldwide. Traditional treatments such as buprenorphine and methadone have proven effective in managing withdrawal symptoms but often struggle with long-term abstinence rates. Researchers are now turning their attention to novel therapies that could enhance existing treatment regimens.

Semaglutide, originally developed for metabolic disorders, has shown promising effects on brain chemistry and behavior due to its impact on the GLP-1 receptor system. This system is known to influence reward pathways in the brain, which could play a role in reducing cravings for opioids. The current trial seeks to build upon this knowledge by investigating semaglutide's potential benefits for individuals with OUD.

Key Details

The clinical trial, identified as NCT06548490 on ClinicalTrials.gov, is currently recruiting participants who are already receiving maintenance treatment with either buprenorphine or methadone. The primary objective of the study is to determine if semaglutide can increase the likelihood that patients will refrain from using illicit and nonprescribed opioids.

Participants in this Phase 2 trial will be randomly assigned to receive either semaglutide via pen injector or a placebo. Both groups will continue their standard treatment with buprenorphine or methadone throughout the study period. Researchers will closely monitor participants for signs of reduced opioid use, improved mental health outcomes, and overall quality of life.

Key Takeaways

  • Semaglutide May Offer New Hope: The trial aims to explore whether semaglutide can serve as an effective adjunctive therapy for patients with OUD.
  • Enhanced Treatment Regimens: By combining semaglutide with existing medications like buprenorphine or methadone, the study seeks to improve long-term abstinence rates and overall recovery outcomes.
  • GLP-1 Receptor System Influence: The research focuses on how activation of the GLP-1 receptor system might impact opioid cravings and behavior.
  • Patient Safety First: As with all clinical trials, patient safety is a top priority. Participants will be closely monitored for any adverse effects.

What This Means

For the peptide community, this trial represents an exciting opportunity to explore new applications of existing therapies. Semaglutide's potential in treating OUD highlights the versatility and expanding scope of peptide therapy beyond metabolic disorders. If successful, this research could pave the way for additional studies on other peptides with similar mechanisms that might offer novel treatments for addiction.

Moreover, the findings from this study could influence future FDA regulations regarding off-label use of semaglutide and set a precedent for further investigation into peptide-based interventions in mental health and substance abuse disorders. This would be a significant step forward in addressing one of the most pressing public health issues of our time.

---

Source: ClinicalTrials.gov — Published 2026-11-17

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.